Gaziantep Islam Science and Technology University Faculty of Medicine, Department of Biophysics, Gaziantep, Turkey.
Fethi Sekin City Hospital Department of Physiology, Elazig, Turkey.
Neuropharmacology. 2025 Feb 1;263:110207. doi: 10.1016/j.neuropharm.2024.110207. Epub 2024 Nov 5.
Neuropathic pain is associated with diverse etiologies, including sciatica, diabetes, and the use of chemotherapeutic agents. Despite the varied origins, mitochondrial dysfunction, oxidative stress, and inflammatory cytokines are recognized as key contributing factors in both the initiation and maintenance of neuropathic pain. The effects of the mitochondrial-derived peptide humanin on neuropathic pain, however, remain unclear, despite its demonstrated influence on these mechanisms in numerous disease models. This study aimed to evaluate the effects of humanin on pain behavior in murine models of metabolic (streptozotocin/STZ), toxic (oxaliplatin/OXA), traumatic (sciatic nerve cuffing/cuff), and neuropathic pain. A secondary objective was to assess whether humanin modulates oxidative damage and inflammatory cytokine levels in these neuropathic pain models. Humanin (4 mg/kg) was administered intraperitoneally (i.p.) to BALB/c male mice with induced neuropathic pain over a period of 15 days, with pain thresholds assessed using hot plate, cold plate, and Von Frey tests. Serum levels of antioxidant enzymes, oxidative stress markers, and inflammatory/anti-inflammatory cytokines were measured via enzyme-linked immunosorbent assay (ELISA). In neuropathic pain-induced mice, humanin administration resulted in a statistically significant increase in pain threshold values in the STZ + Humanin, OXA + Humanin, and cuff + Humanin groups compared to their respective control groups (P < 0.05) over 15 days. Furthermore, humanin treatment significantly elevated antioxidant enzyme levels and anti-inflammatory cytokine concentrations, while reducing oxidative stress markers and pro-inflammatory cytokine levels compared to control groups (P < 0.01). These findings suggest that humanin exhibits therapeutic potential in the treatment of neuropathic pain induced by STZ, OXA, and cuff models. The ability of humanin to mitigate neuropathic pain through the suppression of oxidative stress and inflammatory cytokines indicates its promise as a novel therapeutic strategy.
神经病理性疼痛与多种病因相关,包括坐骨神经痛、糖尿病和化疗药物的使用。尽管病因各异,但线粒体功能障碍、氧化应激和炎症细胞因子被认为是神经病理性疼痛发生和持续的关键因素。尽管人类素在许多疾病模型中对这些机制有影响,但它对神经病理性疼痛的作用仍不清楚。本研究旨在评估人类素对代谢性(链脲佐菌素/STZ)、毒性(奥沙利铂/OXA)、创伤性(坐骨神经套管/套管)和神经病理性疼痛的小鼠模型中疼痛行为的影响。次要目的是评估人类素是否调节这些神经病理性疼痛模型中的氧化损伤和炎症细胞因子水平。在诱导神经病理性疼痛的 BALB/c 雄性小鼠中,通过腹腔内(i.p.)给予人类素(4mg/kg),持续 15 天,通过热板、冷板和 Von Frey 试验评估疼痛阈值。通过酶联免疫吸附试验(ELISA)测量血清抗氧化酶、氧化应激标志物和炎症/抗炎细胞因子的水平。在神经病理性疼痛诱导的小鼠中,与各自的对照组相比,STZ+人类素、OXA+人类素和套管+人类素组在 15 天内接受人类素治疗后,疼痛阈值值显著增加(P<0.05)。此外,与对照组相比,人类素治疗显著提高了抗氧化酶水平和抗炎细胞因子浓度,同时降低了氧化应激标志物和促炎细胞因子水平(P<0.01)。这些发现表明,人类素在治疗 STZ、OXA 和套管模型诱导的神经病理性疼痛方面具有治疗潜力。人类素通过抑制氧化应激和炎症细胞因子减轻神经病理性疼痛的能力表明其作为一种新的治疗策略具有潜力。